AUG 07, 2018 8:30 PM PDT

Potential Bcl-2 Targeted Therapy for Relapsed Multiple Myeloma Patients

WRITTEN BY: Mauri Brueggeman

In June 2018, a new first of its kind drug class for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) was approved by the Food and Drug Administration in the United States.  The target of this new drug class is Bcl-2, which is an apoptotic, or programmed cell death, regulator.  Bcl-2 controls cell death through mitochondrial membrane permeability mechanisms with caspases.  Bcl-2 is located on chromosome 18, and is considered an oncogene; this sequence can, and is, involved in translocations or mutations resulting in deregulation of expression in tumorigenesis.  Tumor cells must survive inhospitable conditions including hypoxia and loss of nutrient supply when they become advanced enough; each of these contribute to tumor cell damage susceptibility and apoptosis.  Tumor cells must adapt by gaining mutations that inhibit that apoptotic process which is what happens with Bcl-2 mutations. 

Bcl-2 family members, there are reported to be about 20 total related proteins, act to create protein channels or pores within the mitochondrial membrane allowing the release of factors like Cytochrome C.  These factors are intermediaries as part of one apoptotic pathway.  When Bcl-2 expression is affected by mutation, these factors cannot be released as a part of the apoptosis mechanism of the cell.

In mutated lymphocytic cells, there is high level of expression of proapoptotic proteins at the ready but they are stuck waiting by the blocked Bcl-2 pathway.  Patients with these primed mutated lymphocytes, like those with CLL, readily die when another apoptotic agent outside of that Bcl-2 mediated pathway is introduced in conjunction with this new drug class. 

Additional investigations are being made using Bcl-2 targeted drugs for other conditions like Multiple Myeloma (MM), which does not involve an altered chromosome 18; MM cells are plasma cells with a translocation between chromosomes 11 and 14.  However, one group of researchers published their investigation in Leukemia on August 3, 2018.  MM patients have overexpression of anti-apoptotic proteins like Bcl-2; they found that combination therapy which included venetoclax, the Bcl-2 targeted drug approved by the FDA in June, had a promising response rate in relapsed myeloma patients.  This type of pretreated myeloma patient has few options for disease free survival long term.  This new approach may prove to be clinically relevant in the near future after further research is conducted.  

Sources: Leukemia, Blood, FDA, BBA Molecular Cell Research,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAY 27, 2021
Cancer
Which ovarian cancer patients will be resistant to platinum chemotherapy?
MAY 27, 2021
Which ovarian cancer patients will be resistant to platinum chemotherapy?
Research published in the journal EMBO Molecular Medicine details a novel mechanism that can be used to predict which ep ...
JUN 07, 2021
Health & Medicine
Higher Incidence of Breast Cancer in Polluted Urban Areas
JUN 07, 2021
Higher Incidence of Breast Cancer in Polluted Urban Areas
A Taiwanese study looked at the incidence of breast cancer in areas of Taiwan with varying levels of air pollutants. Air ...
JUL 30, 2021
Cancer
Obesity Reduces Mortality in Advanced Prostate Cancer
JUL 30, 2021
Obesity Reduces Mortality in Advanced Prostate Cancer
Obese patients with an advanced form of prostate cancer survive longer than their slimmer counterparts, according to res ...
AUG 12, 2021
Clinical & Molecular DX
Computers Pick Up the 'Sound' of Thyroid Cancer
AUG 12, 2021
Computers Pick Up the 'Sound' of Thyroid Cancer
Researchers have developed a new technology for the non-invasive diagnosis of thyroid cancer that combines photoacoustic ...
AUG 18, 2021
Technology
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
AUG 18, 2021
Tracking System Maps How Cancer Cells Evolve, Providing New Treatment Insights
All cells in a tumor share some genetic similarities, but also have key differences, often hindering effective treatment ...
AUG 18, 2021
Cell & Molecular Biology
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
AUG 18, 2021
Insight Into an Antiviral Enzyme That Can Impact Cancer Cells
For many years, researchers have studied how an enzyme called APOBEC3 can help protect the body from pathogenic viruses, ...
Loading Comments...